AVTX financials
Avalo Therapeutics (AVTX) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
AVTX income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $59.00K | – | -$72.92M | -$78.26M | -5.84 |
| 2024 | $441.00K | – | -$68.51M | -$35.13M | -20.91 |
| 2023 | $1.92M | $640.00K | -$27.35M | -$31.54M | -113.58 |
| 2022 | $18.05M | $14.62M | -$37.44M | -$41.66M | -1063.00 |
| 2021 | $5.40M | $3.91M | -$82.13M | -$84.38M | -996.00 |
| 2020 | $6.70M | $6.40M | -$72.84M | -$63.50M | -206.40 |
- AVTX revenue was $59.00K in fiscal 2025, net income -$78.26M.
Updated 2026-11-09 19:47 UTC